Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
about
Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case reportIncidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortField evaluation of a prototype paper-based point-of-care fingerstick transaminase testAdverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medicationChallenges in the treatment of HIV and HCV coinfection.Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South AfricaHepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection TreatmentFactors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAARTAdverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literatureIncidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort studyTreatment of hepatitis C and anemia in human immunodeficiency virus-infected patients.Liver transplantation in HCV/HIV positive patients.Evaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon.Nevirapine induced Stevens-Johnson syndrome in an HIV infected patient.HCV chronic hepatitis in patients with HIV: clinical management issues.Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV.Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection.HIV viral suppression in the era of antiretroviral therapyCanadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice.Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, NigeriaHIV, Hepatitis B, and Hepatitis C in Zambia.Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.HIV and HCV coinfection in haemophilia.Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.Clinical utility of current NNRTIs and perspectives of new agents in this class under development.Nevirapine in the treatment of HIV.Therapies for HIV and viral hepatitis coinfection.Liver enzymes elevation after HAART in HIV-HCV co-infection.The role of the immune system in nevirapine-induced subclinical liver injury of a rat model.Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsMulticenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.Treatment of hepatitis C in HIV-coinfected patients.
P2860
Q24793365-A9115AC9-6765-497E-B795-5470941DDFB3Q24814420-B0E95706-BC1C-4426-8080-492955B3AFBAQ28533930-D1A8C039-414A-4643-AF8B-3D6C0A7F0981Q28749406-6AD0CD7E-735E-4821-B390-B119FEB8E922Q30389282-58357877-AF89-4F08-8C6E-6E5ADAE4522BQ33533366-44CD5220-DB9B-47BB-BB8C-2031974494F1Q33576161-F235485E-0508-4ABF-9555-DBFA6E9F5541Q34070485-8B937FAA-30C9-473D-9F18-2DB9A33DFF14Q34174009-446B18B7-7A4C-4FE3-B0C3-4243396DCD8DQ34444338-71940142-FD10-4B87-8B9A-B1489A2561A2Q34484483-3225CC17-65D8-4522-8822-29E821A1F2BEQ34631679-087E00E5-4A2A-4F61-9497-52AA8A6615DBQ34640985-8FE73AF7-9D0D-464C-BE7E-BB621EF7E3B2Q34670487-6C83F9A0-04B4-4CF4-9BB1-24A6815308E1Q34706519-2F09B52A-1F44-4E73-A76A-0E29FDE85BB0Q34756205-8BD7A3C4-466E-4037-A019-47595B830599Q34785683-ABDDAC73-D9BA-4DDA-B9C2-F3C3098C19EBQ34789841-C6C5ADFA-0FB0-4196-BF78-48CFF9BEB513Q34794696-2921707E-4D73-4FAC-9744-698E542776D2Q34973371-5ACEB2AA-887B-4462-90F8-D11AA072257EQ34998102-A4A04073-97B5-4BBC-83C5-DD8567BB43FCQ35059337-E2B9950A-DFAC-44E9-97AE-20B9517EE73AQ35099547-B443E901-4A27-4BF6-9224-065BEFDDBD8BQ35104583-21259B7A-7DEA-41CD-90EC-E586CEF15852Q35183973-B859828B-32EE-41FB-A4A9-E7F9C21AA8DAQ35635844-3FB1F20C-E1C9-4A22-B258-51623308D24BQ35666754-4212BD34-7CBF-4698-BF17-8AFD73ECC2D2Q35676417-50CF6622-8F6D-4608-8621-82F1780500E4Q35827891-B3638179-8BEE-44A1-A0F7-C1E98BE6DAA8Q35842270-DBF1F9B2-1985-44A2-B060-71C3E1320D1AQ35917412-60693386-2C0A-44E5-8500-737BC4346EC3Q36066218-C1670A9B-3CBA-4A3A-90EB-C92B9D1A3A57Q36177726-405F4436-9DC2-4892-ABDC-B5E2C06B2840Q36200176-EA5DC334-07B7-4497-9E47-364ADB2A4C9AQ36235489-8245C592-9637-4970-85BE-3D451DFF2AA3Q36276597-65AA79F0-ABA8-4144-83A8-8C75978E1647Q36286145-D0A93FD5-284D-4EE4-95C3-9798439673B9Q36336929-65443FAD-8767-4A48-AB68-E64436E03DD1Q36402487-C5E93000-D8DD-4664-A9D5-D0FBC7B477CBQ36409500-66B5DEB5-B2C7-4336-A74B-5F441F0174A5
P2860
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Hepatotoxicity in HIV-1-infect ...... aining antiretroviral therapy.
@en
Hepatotoxicity in HIV-1-infect ...... aining antiretroviral therapy.
@nl
type
label
Hepatotoxicity in HIV-1-infect ...... aining antiretroviral therapy.
@en
Hepatotoxicity in HIV-1-infect ...... aining antiretroviral therapy.
@nl
prefLabel
Hepatotoxicity in HIV-1-infect ...... aining antiretroviral therapy.
@en
Hepatotoxicity in HIV-1-infect ...... aining antiretroviral therapy.
@nl
P2093
P1433
P1476
Hepatotoxicity in HIV-1-infect ...... aining antiretroviral therapy.
@en
P2093
García-Viejo MA
Mallolas J
Martínez E
P304
P356
10.1097/00002030-200107060-00007
P407
P577
2001-07-01T00:00:00Z